What is Northland Capmk’s Forecast for BLFS Q1 Earnings?

BioLife Solutions, Inc. (NASDAQ:BLFS) – Equities researchers at Northland Capmk issued their Q1 2026 earnings per share estimates for BioLife Solutions in a research note issued on Monday, January 5th. Northland Capmk analyst C. Byrnes forecasts that the medical equipment provider will post earnings per share of $0.01 for the quarter. The consensus estimate for BioLife Solutions’ current full-year earnings is ($0.30) per share. Northland Capmk also issued estimates for BioLife Solutions’ Q2 2026 earnings at $0.02 EPS, Q3 2026 earnings at $0.03 EPS, Q4 2026 earnings at $0.03 EPS and FY2027 earnings at $0.25 EPS.

BLFS has been the subject of a number of other research reports. Northland Securities set a $34.00 price objective on shares of BioLife Solutions in a report on Monday. Zacks Research cut shares of BioLife Solutions from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 8th. Wall Street Zen downgraded shares of BioLife Solutions from a “buy” rating to a “hold” rating in a report on Sunday, November 30th. HC Wainwright reiterated a “buy” rating and issued a $32.00 price objective on shares of BioLife Solutions in a report on Monday, December 29th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of BioLife Solutions in a research report on Wednesday, October 8th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $32.00.

BioLife Solutions Stock Performance

NASDAQ BLFS opened at $26.35 on Tuesday. The stock’s fifty day moving average is $25.56 and its two-hundred day moving average is $24.80. The firm has a market capitalization of $1.27 billion, a P/E ratio of -376.37 and a beta of 1.93. BioLife Solutions has a fifty-two week low of $19.10 and a fifty-two week high of $29.62.

Hedge Funds Weigh In On BioLife Solutions

Several institutional investors have recently modified their holdings of BLFS. Amalgamated Bank raised its stake in shares of BioLife Solutions by 3.5% in the third quarter. Amalgamated Bank now owns 10,898 shares of the medical equipment provider’s stock valued at $278,000 after acquiring an additional 366 shares in the last quarter. Ameritas Investment Partners Inc. increased its holdings in BioLife Solutions by 12.8% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,873 shares of the medical equipment provider’s stock worth $83,000 after purchasing an additional 441 shares during the period. Louisiana State Employees Retirement System raised its position in BioLife Solutions by 2.9% in the 3rd quarter. Louisiana State Employees Retirement System now owns 17,800 shares of the medical equipment provider’s stock valued at $454,000 after purchasing an additional 500 shares in the last quarter. Isthmus Partners LLC boosted its stake in shares of BioLife Solutions by 0.4% in the 2nd quarter. Isthmus Partners LLC now owns 132,125 shares of the medical equipment provider’s stock valued at $2,846,000 after buying an additional 509 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its stake in shares of BioLife Solutions by 2.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 20,764 shares of the medical equipment provider’s stock valued at $447,000 after buying an additional 555 shares during the period. Institutional investors and hedge funds own 93.24% of the company’s stock.

Insider Activity

In related news, CFO Troy Wichterman sold 30,000 shares of the firm’s stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $25.72, for a total transaction of $771,600.00. Following the completion of the transaction, the chief financial officer directly owned 152,769 shares in the company, valued at $3,929,218.68. This trade represents a 16.41% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Casdin Partners Master Fund, L sold 750,000 shares of the stock in a transaction dated Wednesday, October 15th. The stock was sold at an average price of $28.55, for a total transaction of $21,412,500.00. Following the sale, the insider directly owned 5,957,165 shares in the company, valued at $170,077,060.75. This represents a 11.18% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 937,664 shares of company stock worth $26,311,309 in the last quarter. Insiders own 2.20% of the company’s stock.

BioLife Solutions Company Profile

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.